Drug intelligence / Profile preview

OTG177

Development stage: Preclinical
Lead developer: Octagon Therapeutics
Modality: Small Molecules

Overview

OTG177 is an investigational small‑molecule immunomodulator being developed by Octagon for autoimmune blistering skin diseases, particularly pemphigus and pemphigoid. Based on company disclosures, the compound is designed to selectively inhibit metabolically reprogrammed autoreactive B cells that drive pathogenic autoantibody production in these disorders, while sparing normal immune responses, representing a targeted, B cell–directed approach potentially applicable across a broad range of autoimmune diseases.[9]

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on OTG177.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTG177.

Explore the full profile